HUP0204026A2 - Cefuroxime axetilt tartalmazó gyógyszerkészítmény - Google Patents

Cefuroxime axetilt tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0204026A2
HUP0204026A2 HU0204026A HUP0204026A HUP0204026A2 HU P0204026 A2 HUP0204026 A2 HU P0204026A2 HU 0204026 A HU0204026 A HU 0204026A HU P0204026 A HUP0204026 A HU P0204026A HU P0204026 A2 HUP0204026 A2 HU P0204026A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
cefuroxime axetil
composition containing
containing cefuroxime
axetil
Prior art date
Application number
HU0204026A
Other languages
English (en)
Inventor
Matilde Ibánez Fernández
Emilio Sanz Gárriz
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Publication of HU0204026D0 publication Critical patent/HU0204026D0/hu
Publication of HUP0204026A2 publication Critical patent/HUP0204026A2/hu
Publication of HUP0204026A3 publication Critical patent/HUP0204026A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Cefuroxime axetilt tartalmazó részecske formájú összetétel, melyhez arészecskéket integrált lipid vagy lipidkeverék bevonattal biztosítják,melyek vízben oldhatatlanok, mely összetételben található továbbáédesítőrendszer és textúramódosító olyan mennyiségben, mely acefuroxime axetil keserű ízét orális beadáskor elfedi. Ó
HU0204026A 2001-11-23 2002-11-21 Pharmaceutical composition containing cefuroxime axetil HUP0204026A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (3)

Publication Number Publication Date
HU0204026D0 HU0204026D0 (en) 2003-01-28
HUP0204026A2 true HUP0204026A2 (hu) 2003-08-28
HUP0204026A3 HUP0204026A3 (en) 2004-09-28

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204026A HUP0204026A3 (en) 2001-11-23 2002-11-21 Pharmaceutical composition containing cefuroxime axetil

Country Status (34)

Country Link
US (1) US20030161888A1 (hu)
EP (1) EP1446126B1 (hu)
JP (1) JP3497503B2 (hu)
KR (1) KR100979328B1 (hu)
CN (1) CN1297274C (hu)
AT (1) ATE473006T1 (hu)
AU (2) AU2002338950A1 (hu)
BE (2) BE1014078A6 (hu)
BR (1) BR0204767A (hu)
CA (1) CA2408198C (hu)
CH (1) CH693982A5 (hu)
CO (1) CO5580783A2 (hu)
CY (1) CY1110778T1 (hu)
CZ (1) CZ12993U1 (hu)
DE (3) DE10254412A1 (hu)
DK (1) DK1446126T3 (hu)
ES (2) ES2201932B2 (hu)
FR (1) FR2832635B1 (hu)
GB (1) GB2383536B (hu)
GR (1) GR1004522B (hu)
HR (2) HRP20020923A2 (hu)
HU (1) HUP0204026A3 (hu)
IL (2) IL161972A0 (hu)
IT (1) ITMI20022470A1 (hu)
MX (1) MXPA02011561A (hu)
NO (1) NO335273B1 (hu)
NZ (1) NZ533092A (hu)
PL (1) PL205325B1 (hu)
PT (1) PT1446126E (hu)
RU (1) RU2241460C2 (hu)
SI (1) SI1446126T1 (hu)
TR (1) TR200202559A2 (hu)
WO (1) WO2003043638A1 (hu)
ZA (1) ZA200209473B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) * 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
UY33173A (hu) * 2010-01-08 2011-07-29 Eurand Inc
EP2566458B1 (en) 2010-05-04 2015-08-05 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
US9278099B2 (en) 2011-10-31 2016-03-08 Novartis Ag Pazopanib formulation
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
CN1297274C (zh) 2007-01-31
DE60236952D1 (de) 2010-08-19
KR20050044590A (ko) 2005-05-12
BE1015217A5 (hu) 2004-11-09
AU2002338950A1 (en) 2003-06-10
GR1004522B (el) 2004-04-06
IL161972A0 (en) 2005-11-20
AU2002302147B2 (en) 2005-01-20
TR200202559A2 (tr) 2003-06-23
PL357259A1 (en) 2003-06-02
FR2832635B1 (fr) 2006-04-21
HUP0204026A3 (en) 2004-09-28
NO335273B1 (no) 2014-11-03
KR100979328B1 (ko) 2010-08-31
ZA200209473B (en) 2003-06-10
IL161972A (en) 2009-06-15
JP3497503B2 (ja) 2004-02-16
EP1446126A1 (en) 2004-08-18
US20030161888A1 (en) 2003-08-28
FR2832635A1 (fr) 2003-05-30
NZ533092A (en) 2006-02-24
PL205325B1 (pl) 2010-04-30
CZ12993U1 (cs) 2003-02-10
ITMI20022470A1 (it) 2003-05-24
NO20042620L (no) 2004-06-22
CA2408198C (en) 2004-03-09
ES2201932A1 (es) 2004-03-16
CY1110778T1 (el) 2015-06-10
CN1421206A (zh) 2003-06-04
GB2383536B (en) 2003-11-19
ES2201932B2 (es) 2005-03-16
JP2003160493A (ja) 2003-06-03
CH693982A5 (de) 2004-05-28
DE10254412A1 (de) 2003-06-12
BE1014078A6 (fr) 2003-03-04
RU2241460C2 (ru) 2004-12-10
ATE473006T1 (de) 2010-07-15
CA2408198A1 (en) 2003-02-02
DK1446126T3 (da) 2010-10-11
ES2347536T3 (es) 2010-11-02
DE20218068U1 (de) 2003-03-27
HRP20020923A2 (en) 2003-10-31
GB0227215D0 (en) 2002-12-24
MXPA02011561A (es) 2005-07-13
WO2003043638A1 (en) 2003-05-30
PT1446126E (pt) 2010-09-24
SI1446126T1 (sl) 2010-10-29
CO5580783A2 (es) 2005-11-30
GB2383536A (en) 2003-07-02
EP1446126B1 (en) 2010-07-07
HU0204026D0 (en) 2003-01-28
HRP20020924A2 (en) 2003-10-31
GR20020100506A (el) 2003-07-16
BR0204767A (pt) 2003-09-16

Similar Documents

Publication Publication Date Title
HUP0204026A2 (hu) Cefuroxime axetilt tartalmazó gyógyszerkészítmény
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
HUP0204409A2 (en) Sustained release ranolazine pharmaceutical compositions
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
WO2002047607A3 (en) Process for the preparation of a fast dissolving dosage form
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2002094774A3 (en) Oxcarbazepine dosage forms
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine
WO2004073686A3 (en) Menthol solutions of drugs
BR0307048A (pt) Composição farmacêutica orodispersìvel de perindoprila
AP2001002369A0 (en) Pharmaceutical complex.
WO2007054139A3 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
MXPA05010135A (es) Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.
MXPA06000712A (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico.
HUP0302294A2 (hu) L-karnitin és alkanoil-L-karnitin taurin-kloriddal és glicin-kloriddal alkotott nem higroszkópos sói és ezeket tartalmazó, orális beadásra alkalmas szilárd készítmények
PL1663101T3 (pl) Postać stosowana do doustnego podawania substancji czynnych, witamin i/lub substancji odżywczych, zestaw i zastosowanie
MXPA05011671A (es) Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos.
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
WO2006053778A3 (en) Amide derivatives, their manufacture and use as pharmaceutical agents
WO2006111296A3 (de) Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees